Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers Results available

CYP2B6 Polymorphisms in Ketamine

NCT01988922
Conditions
Healthy Volunteers
Interventions
ketamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Anorexia Nervosa
Interventions
Ketamine Hcl 50Mg/Ml Inj
Drug
Lead sponsor
Homeostasis Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Windsor, Connecticut
Conditions
Suicidal Ideation
Interventions
Ketamine (Ketalar), Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Repeated Neurocognitive Measurements in Depressed Patients

NCT04916548
Conditions
Depression, Unipolar
Interventions
Intravenous Ketamine
Drug
Lead sponsor
Rebecca Price
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Obsessive Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Recruiting No phase listed Observational

The OBSERVE Protocol

NCT06725277
Conditions
Major Depression Disorder
Interventions
Spravato, IV Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more
Conditions
Depression
Interventions
Racemic ketamine, Spravato (Esketamine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more
Conditions
Depression, Unipolar
Interventions
Intravenous Ketamine
Drug
Lead sponsor
Jay Fournier
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Depressive Disorder, Major, Suicidal
Interventions
SLS-002, Placebo, Standard of care, Intranasal device
Drug · Other · Device
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Orange, California • Panorama City, California • San Diego, California + 18 more
Conditions
PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder, Traumatic Brain Injury
Interventions
IV ketamine, Midazolam
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Pain, Postoperative, Arthroplasty Complications
Interventions
Ketamine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine hydrochloride infusion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Ketamine + Mindfulness for Depression

NCT05168735
Conditions
Depression, Unipolar
Interventions
Intravenous Ketamine, Brief Mindfulness Exercises, Academic Exercises
Drug · Behavioral
Lead sponsor
Rebecca Price
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Drug Abuse
Interventions
Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Completed Phase 1Phase 2 Interventional Results available

Ketamine and Prolonged Exposure in PTSD

NCT03960658
Conditions
Post-traumatic Stress Disorder
Interventions
ketamine-enhanced prolonged exposure
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
Interventions
Midazolam, Ketamine
Drug
Lead sponsor
Dennis Charney
Other
Eligibility
21 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Terminated Phase 1 Interventional Accepts healthy volunteers

The Effects of Low Dose Ketamine on Cardiovascular Function

NCT04429685
Conditions
Healthy
Interventions
Ketamine, Saline (placebo)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas